Table 3. Selected trials of radio(chemo)therapy combined with antiangiogenic agents in NSCLC.

Therapy	Trial ID, ref.	Phase	No pts/stage	Induction	Concurrent	Consolidative/maintenance	RT	Median OS (months)	Toxicity
Tha	ECOG 3598, Hoang et al., (69)	III	546/III	Arm A: Pac + Car	Arm A: Pac/Car	Arm A: –	60 Gy/30 fx	Arm A: 15.3	Arm A: G≥3 thromboembolic events 3%, fatigue 6%, sensory neuropathy 6%, dizziness 1%, decreased consciousness 1%
				Arm B: Pac + Car + Thalidomide	Arm B: Pac/Car + Tha	Arm B: thalidomide		Arm B: 16	Arm B: G≥3 thromboembolic events 11%, fatigue 11%, sensory neuropathy 11%, dizziness 6%, decreased consciousness 5%, no increased radiation-related toxicities
Bev	Lind et al., (70)	I	6/III	Cis-based	Bev 7.5 mg/kg, 15 mg/kg	–	66 Gy/33 fx	N/A	G3 pneumonia 2 pts, G2 pneumonia 2 pts
Bev	Socinski et al., (72)	II	45/III	Pac + Car + Bev	Pac/Car + Bev +/− erlotinib	Bev +/− erlotinib	74 Gy/37 fx	18.4	G3/4 esophagitis 29%, G≥3 esophagitis 54%, tracheoesophageal fistula 1 pt
Bev	SWOG S0533, Wozniak et al., (73)		Low risk strata: 16	–	Eto/Cis+ Cohort 1: no Bev	Doc+ Bev	64.8 Gy/36 fx	46	Low risk strata—CRT. G3/4 neutropenia 4 pts, esophagitis 1 pt, Consolidation phase: G3 pneumonitis 1 pt
					Cohort 2: Bev d. 15,36,57
			High risk strata: 12/III		Cohort 3: Bev d. 1,22,43			17	High risk strata—CRT. G3/4 neutropenia 6 pts, G3 pneumonitis 1 pt, esophagitis 1 pt, Consolidation phase: G5 hemorrhage 2 pts, G3 hemorrhage 1 pt, G3 pneumonitis 1 pt

Ref, reference; Tha, Thalidomide; Bev, bevacizumab; pt, patient; Pac, Paclitaxel; Cis, Cisplatin; Car, Carboplatin; Doc, Docetaxel; Eto, Etoposide.